SCHEMBL3760587

SCHEMBL3760587

CC1(C)CC(=O)c2sc(N3CCOCC3)c(-c3ccnc(-c4cccc(CN5CC[C@H](N)C5)c4)c3)c2C1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PRKACA P17612 3/20 0.38
PRKACG P22612 3/20 0.38
PRKACB P22694 3/20 0.38
KDM1A O60341 1/20 0.34
MAPKAPK2 P49137 1/20 0.33
PSMB8 P28062 1/20 0.33
MTOR P42345 2/20 0.33
BUB1 O43683 1/20 0.33
LRRK2 Q5S007 2/20 0.33
PIK3CA P42336 3/20 0.32
PIM1 P11309 2/20 0.32
PIK3CD O00329 2/20 0.32
PIK3CB P42338 2/20 0.32
PIK3CG P48736 2/20 0.32
PARP1 P09874 1/20 0.32
PARP2 Q9UGN5 1/20 0.32
USP7 Q93009 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3755059 1.00 PRKACA (0.38) PRKACAPRKACGPRKACBKDM1AMAPKAPK2
SCHEMBL3754902 0.96 PSMB8 (0.35) PRKACAPRKACGPRKACBMAPKAPK2PSMB8
SCHEMBL3763610 0.92 MTOR (0.40) MAPKAPK2PSMB8MTORBUB1LRRK2
SCHEMBL3760623 0.91 PSMB8 (0.41) MAPKAPK2PSMB8BUB1LRRK2PIK3CA
SCHEMBL16161763 0.90 MAPKAPK2 (0.34) MAPKAPK2PSMB8BUB1PIK3CAPIK3CD
SCHEMBL3762537 0.89 PRKACA (0.41) PRKACAPRKACGPRKACBKDM1APSMB8
SCHEMBL3760242 0.89 PSMB8 (0.38) MAPKAPK2PSMB8MTORBUB1LRRK2
SCHEMBL3760629 0.89 MAPKAPK2 (0.34) MAPKAPK2PSMB8BUB1LRRK2PIK3CA
SCHEMBL3760485 0.89 MAPKAPK2 (0.36) MAPKAPK2PSMB8MTORBUB1LRRK2
SCHEMBL3751951 0.89 PIK3CA (0.36) MAPKAPK2PSMB8MTORBUB1PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA PRKACA 155/4885PRKACG 197/4885PRKACB 223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.